More Impact AG Secures US Patent for Speedinject Technology

More Impact AG, a high-tech medical firm based in Frankfurt, announced the granting of a US patent for its Speedinject technology. Developed by its subsidiary, The Key Unternehmensberatung GmbH, Speedinject enables needle-free drug administration. It targets the US market, offering an eco-friendly solution primarily for diabetes and weight loss treatments, where demand is rising.

The innovative system replaces needles with an electromagnetically driven mechanism ensuring precise, painless, and waste-minimizing injections. A biodegradable cartridge option is also underway. Market projections indicate a growth exceeding 18% in weight loss injections globally by 2030, underlining the technology’s potential.

With the world's largest US pharmaceutical market, valued at USD 634 billion in 2024, expanding to USD 884 billion over five years, More Impact plans to launch Speedinject in the US by late 2025. This patent secures their international growth strategy and promises significant economic benefits.